Novan (NASDAQ: NOVN) is one of 19 publicly-traded companies in the “Specialty & Advanced Pharmaceuticals” industry, but how does it compare to its competitors? We will compare Novan to related businesses based on the strength of its risk, dividends, institutional ownership, valuation, earnings, analyst recommendations and profitability.


This table compares Novan and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Novan N/A -194.61% -99.61%
Novan Competitors -538.85% -41.85% -24.81%

Insider and Institutional Ownership

6.1% of Novan shares are owned by institutional investors. Comparatively, 66.4% of shares of all “Specialty & Advanced Pharmaceuticals” companies are owned by institutional investors. 10.7% of Novan shares are owned by company insiders. Comparatively, 10.0% of shares of all “Specialty & Advanced Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Novan and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Novan 0 1 3 0 2.75
Novan Competitors 63 299 947 27 2.70

Novan presently has a consensus price target of $16.74, suggesting a potential upside of 224.47%. As a group, “Specialty & Advanced Pharmaceuticals” companies have a potential upside of 17.42%. Given Novan’s stronger consensus rating and higher probable upside, equities analysts plainly believe Novan is more favorable than its competitors.

Earnings and Valuation

This table compares Novan and its competitors gross revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Novan $768,999.00 -$49.04 million -0.65
Novan Competitors $2.40 billion $905.93 million 1.01

Novan’s competitors have higher revenue and earnings than Novan. Novan is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.


Novan competitors beat Novan on 6 of the 11 factors compared.

Novan Company Profile

Novan, Inc. is a late-stage pharmaceutical company. The Company is engaged in the development and commercialization of therapies using its nitric oxide platform. The Company develops product candidates using its Nitricil technology, which enables the Company to engineer tunable new chemical entities (NCEs). The Company’s formulation science enables it to further tune the release of nitric oxide when applied to the skin by using the combinations of inactive ingredients. It is developing SB204 for the treatment of acne vulgaris in Phase III. The Company is developing its product candidate, SB206, for the treatment of external genital and perianal warts in Phase II. It is developing SB208, an investigational topical anti-fungal for the treatment of fungal infections of the skin and nails. It is developing SB204 for the treatment of inflammatory skin diseases. Its pipeline also includes SB414, a topical cream product candidate.

Receive News & Stock Ratings for Novan Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novan Inc and related stocks with our FREE daily email newsletter.